[{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"||ARK5\/CDK4\/CDK6\/CSF-1R\/FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconova Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Onconova Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncolytics Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncolytics Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ New Enterprise Associates","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ New Enterprise Associates"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palbociclib","moa":"||CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"||CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase II","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"UNICANCER","sponsor":"Agendia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase II","graph3":"UNICANCER","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UNICANCER \/ Agendia","highestDevelopmentStatusID":"8","companyTruncated":"UNICANCER \/ Agendia"},{"orgOrder":0,"company":"Akershus University Hospital","sponsor":"Novartis Pharmaceuticals Corporation | Vestre Viken Hospital Trust","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase II","graph3":"Akershus University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akershus University Hospital \/ Novartis Pharmaceuticals Corporation | Vestre Viken Hospital Trust","highestDevelopmentStatusID":"8","companyTruncated":"Akershus University Hospital \/ Novartis Pharmaceuticals Corporation | Vestre Viken Hospital Trust"},{"orgOrder":0,"company":"Laboratorios Farmaceuticos Rovi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Laboratorios Farmaceuticos Rovi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Laboratorios Farmaceuticos Rovi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Laboratorios Farmaceuticos Rovi \/ Undisclosed"},{"orgOrder":0,"company":"Spanish Breast Cancer Research Group","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase II","graph3":"Spanish Breast Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spanish Breast Cancer Research Group \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Spanish Breast Cancer Research Group \/ Eli Lilly"},{"orgOrder":0,"company":"Gynuity Health Projects","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Gynuity Health Projects","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gynuity Health Projects \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gynuity Health Projects \/ Undisclosed"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Eli Lilly | Cancer Prevention Research Institute of Texas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UT Southwestern Medical Center \/ Eli Lilly | Cancer Prevention Research Institute of Texas","highestDevelopmentStatusID":"8","companyTruncated":"UT Southwestern Medical Center \/ Eli Lilly | Cancer Prevention Research Institute of Texas"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Context Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Context Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Context Therapeutics"},{"orgOrder":0,"company":"Agendia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase III","graph3":"Agendia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agendia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Agendia \/ Undisclosed"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Egymedicalpedia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Egymedicalpedia \/ Undisclosed"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Ain Shams University","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Egymedicalpedia \/ Ain Shams University","highestDevelopmentStatusID":"6","companyTruncated":"Egymedicalpedia \/ Ain Shams University"},{"orgOrder":0,"company":"Yongsheng Wang","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase IV","graph3":"Yongsheng Wang","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yongsheng Wang \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"11","companyTruncated":"Yongsheng Wang \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Nicholas Macklon","sponsor":"Gedeon Richter | Igenomix","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Undisclosed","graph2":"Phase II","graph3":"Nicholas Macklon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nicholas Macklon \/ Gedeon Richter | Igenomix","highestDevelopmentStatusID":"8","companyTruncated":"Nicholas Macklon \/ Gedeon Richter | Igenomix"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Onapristone","moa":"||Progesterone receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Menarini","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Alisertib","moa":"||Serine\/threonine-protein kinase Aurora-A","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Enteric Coated","sponsorNew":"Puma Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Letrozole

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Amcenestrant,Letrozole

                          Therapeutic Area : Oncology

                          Study Phase : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Amcenestrant (SAR439859) is an orally bioavailable SERD that demonstrates pure ER antagonism in vivo. Compared with other SERD agents, amcenestrant provides optimal ER antagonism and degradation.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 17, 2022

                          Lead Product(s) : Amcenestrant,Letrozole

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          02

                          Lead Product(s) : Letrozole

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Letrozole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 17, 2011

                          Lead Product(s) : Letrozole

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          03

                          Lead Product(s) : Letrozole

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Letrozole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 14, 2011

                          Lead Product(s) : Letrozole

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          04

                          CSPC ZhongQi

                          Country arrow
                          Luxepack
                          Not Confirmed

                          CSPC ZhongQi

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Details : Letrozole is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 04, 2025

                          Lead Product(s) : Letrozole

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : MLN8237 (alisertib) is a high affinity, selective, orally bioavailable inhibitors of Aurora A. It is being developed for the treatment of HER2-negative, HR-positive metastatic breast cancer.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 20, 2024

                          Lead Product(s) : Alisertib,Anastrozole,Letrozole

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Egymedicalpedia

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Egymedicalpedia

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Details : Letrozole is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Polycystic Ovary Syndrome.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 18, 2024

                          Lead Product(s) : Letrozole

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Undisclosed

                          Sponsor : Ain Shams University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Egymedicalpedia

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Egymedicalpedia

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Details : Letrozole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Polycystic Ovary Syndrome.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 16, 2024

                          Lead Product(s) : Letrozole

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Proceeds will advance Avenzo’s ARTS-021, a selective CDK2 inhibitor in a Phase 1 study for HR+/HER2- metastatic breast cancer and other advanced solid tumors.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          March 26, 2024

                          Lead Product(s) : AVZO-021,Fulvestrant,Letrozole

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : New Enterprise Associates

                          Deal Size : $150.0 million

                          Deal Type : Series A Financing

                          blank

                          09

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Letrozole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 18, 2024

                          Lead Product(s) : Letrozole

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : ON123300 (narazaciclib) is a multi-kinase inhibitor targeting CDK 4, CDK 6, and other kinases important for cell proliferation and motility. It is being investigated in combination with letrozole in recurrent metastatic low-grade endometrioid endometrial...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 11, 2023

                          Lead Product(s) : Narazaciclib,Letrozole

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank